Amplification of genes at 11q13 in relation to HPV status in head and neck squamous cell carcinomas by Rodrigo, Juan P. et al.
page 52 7th ICHNO
7th ICHNO Conference 
International Conference on innovative approaches in Head and Neck Oncology 






Purpose or Objective 
Oropharyngeal squamous cell carcinoma (OPSCC) is now 
the most common form of head and neck cancer in many 
western countries due to HPV. Patients with HPV-related 
(HPV+) OPSCC have clearly better outcomes after 
treatment. This has led to a strong wish to individualize 
treatment for these patients, aiming to minimize 
morbidity as well as to increase survival. However, 
patients with HPV+ OPSCC and a significant history of 
former or current tobacco smoking (HPV+ smokers) have 
increased risk of locoregional failure and increased cancer 
mortality after radiotherapy-based treatment than HPV+ 
non-smokers. These observations, recently confirmed in 
the MARCH-HPV meta-analysis of individual patient data, 
has led to the hypothesis that HPV+ smokers have altered 
disease biology, possibly through the additional 
accumulation of somatic tumor mutations through 
cumulative carcinogenic exposure.This was a hypothesis-
generating study with the aim of characterizing the 
biology of OPSCC with regards to HPV and tobacco 
smoking, and to clarify whether HPV+ OPSCC consists of 
different biological subgroups, and whether these could 
be related to tobacco smoking. 
Material and Methods 
We included 64 patients with primary, untreated 
oropharyngeal squamous cell carcinoma from two 
prospective protocols. Tumors were comprehensively 
characterized using targeted sequencing of 409 cancer 
related genes with regards to mutations and copy-number 
alterations. Also, we characterized gene expression 
related to HPV, hypoxia, gene expression subtypes and 
radiosensitivity. 
Results 
Fifty-seven patients were available for analysis, of which 
41 were HPV-positive. Twenty patients had a history of 
significant tobacco smoking (≥10 pack-years). Sequencing 
revealed robust differences between HPV+ and HPV- 
tumors (TP53, p<0.0001). Between HPV+ smokers and 
HPV+ non-smokers, there was a distinct pattern of 
amplifications of a number of neighboring genes among 
smokers (p<0.005).These recurrent amplifications among 
HPV+ smokers defined a subgroup of patients (n=20) with 
a distinct mutational profile as well as substantial 
differences in expression of genes related to stem cells 
and gene expression subtypes. 
Conclusion 
HPV+ OPSCC possibly consists of several biologic 
subgroups, related to tobacco smoking, explaining the 
diverse outcomes seen among these patients. These 
subgroups can be characterized by specific DNA copy 
number alterations and mutations. These differences 
could explain the poorer prognosis of HPV+ smokers after 
radiotherapy-based treatment. These findings warrant 
further large-scale investigation to clarify prognostic 
value and potential as biomarkers to guide treatment 
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Purpose or Objective 
Clear differences have been established between head 
and neck squamous cell carcinomas (HNSCC) depending on 
human papillomavirus (HPV) infection status. This study 
investigates the specific role of CTTN, 
CCND1 and ANO1 genes mapping at 11q13 amplicon in 
relation to HPV status in HNSCC patients 
Material and Methods 
CTTN, CCND1 and ANO1 protein expression and gene  
Amplification were respectively analyzed by 
immunohistochemistry and real-time PCR in a 
homogeneous cohort of 392 surgically treated HNSCC 
patients. Results were further confirmed using an 
independent cohort of 279 TCGA HNSCC patients. The 
impact on patient survival was also evaluated. 
Results 
CTTN, CCND1 and ANO1 gene amplification and protein 
expression is frequent in HPV-negative tumors, while 
absent or rare in HPV-positive tumors. Using an 
independent validation cohort of 279 HNSCC patients, we 
consistently found that these three genes are frequently 
co-amplified (28%) and overexpressed (39-46%) in HPV-
negative tumors, whereas almost absent in HPV-positive 
tumors. Remarkably, these alterations (in particular CTTN 
and ANO1 overexpression) were associated with poor 
prognosis. 
Conclusion 
Taken together, distinctive expression/amplification of 
these genes could cooperatively contribute to the 
differences on prognosis and clinical outcome between 
HPV-positive and HPV-negative tumors. These findings 
could serve as the basis to design more personalized 
therapeutic strategies for HNSCC patients 
 
